SciELO - Scientific Electronic Library Online

 
vol.16 issue28Fulfillment of the normatividad in the advertising medicine of free sale in ColombiaCytokine levels in serum of heroin addicts under active consumption or methadone maintenance therapy and healthy control in Pereira (Colombia) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Investigaciones Andina

Print version ISSN 0124-8146

Abstract

MACHADO ALBA, Jorge Enrique; MORALES PLAZA, Cristhian David  and  HOYOS SOTO, Valentina. Frequency of risk potential drug interactions between antiretrovirals and other drugs in Colombian patients. Investig. andina [online]. 2014, vol.16, n.28, pp.910-920. ISSN 0124-8146.

Objectiv: determine the prevalence of potential risk drug interactions between antiretroviral and other drugs in Colombian patients with HIV/AIDS. Materials and methods: cross-sectional study who took the prescription drugs a population database of 6.2 million users from May 1 to July 31, 2012. To identify potential interactions, we sought dispensing antiretrovirals: Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Inhibitors of Reverse Transcriptase (NNRTIs), Protease Inhibitors (PIs), integrase inhibitors, CCR5 antagonists and fusion inhibitors with other risk drugs because their ineffectiveness or toxicity. Analysis by SPSS 21.0. Results: 968 patients were obtained, mostly men (n = 844, 87.2%), mean age 41.6±10.5 years (range: 3-75 years) and male:female ratio of 5.8:1, from 25 cities. In total we found 49 associations of risk; the IPs being involved in 40 cases. The most common interaction was between IPs and statins (OR: 29.5, 95%CI:14,837-58, 785, p <0.001), IPs and antidepressants (OR: 29.5, 95%CI:11,891-73, 266, p <0.001), and corticosteroids (OR: 15.5, 95%CI:4,938-49, 698, p<0.001) and between NNRTIs with warfarin (OR: 46.3, 95% CI :4,108-520, 764, p<0.001). Receive ritonavir became an potential risk factor interactions (OR: 6.7, 95% IC:3.562-12.934; p<0.001) between people living in the Manizales with other places (OR: 3.7, 95%IC:1.043-12.909; p=0.030). Conclusions: the potential interactions between antiretrovirals and other drug groups are common. It is imperative prior assessment and continuous monitoring patients undergoing risk. We recommend similar strategies to those of the current work to strengthen pharmacovigilance programs.

Keywords : Pharmacoepidemiology; Pharmacovigilance; Anti-Ret;roviral Agents; HIV Infections; Acquired Immunodeficiency Syndrome; Drug Interactions; Colombia.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License